CATX

Perspective Therapeutics is a pre-revenue, clinical-stage radiopharmaceutical developer whose entire value rests on early trials of its Lead-212 alpha-therapy platform (VMT-α-NET in neuroendocrine tumors, VMT01 in melanoma, PSV359 in solid tumors). There is no commercial product and effectively no product revenue — the last recorded figure is a trivial $1.43M in FY2023, and FY2024/FY2025 revenue is not even reported. Every headline 'valuation' ratio is meaningless here: a 288x P/S and a -7,919% operating margin are artifacts of a company with a $414M market cap and no sales, not signals to trade on. The FY2025 net loss was -$103M (down 30% YoY) on -$82.5M of operating cash burn, and R&D more than doubled to $84.2M as trials expanded. This is a cash-incinerating research program, and it must be judged as one.

The balance sheet is the crux and it is stretched. Cash fell 50% to just $30.6M at FY2025, while operating cash outflow ran at -$82.5M annually — roughly four months of runway on the year-end cash figure alone. Management asserts resources are sufficient 'to fund our current planned clinical milestones and operational investments into late 2027,' which is only credible because the share count already ballooned 53.9% in a single year (to 114M) — i.e., holders are being diluted heavily to keep the lights on, and the MD&A explicitly flags an ongoing 'need for or ability to obtain additional funding before we can expect to generate any revenue.' Equity fell 28.8% to $207M and the accumulated deficit deepened to -$335M. Debt is negligible (liabilities/equity 0.29x), so bankruptcy risk is low, but survival is a function of repeatedly selling stock at whatever price the market allows — a structural headwind to per-share value.